Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Diabetes

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 58 articles:
HTML format
Text format



Single Articles


    April 2019
  1. TUTTLE KR
    A turning point for chronic kidney disease in diabetes.
    Lancet. 2019 Apr 12. pii: S0140-6736(19)30855.
    PubMed     Text format    


  2. HEERSPINK HJL, Parving HH, Andress DL, Bakris G, et al
    Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
    Lancet. 2019 Apr 12. pii: S0140-6736(19)30772.
    PubMed     Text format     Abstract available


    March 2019
  3. THE LANCET
    Gestational diabetes in England: cause for concern.
    Lancet. 2019;393:1262.
    PubMed     Text format    


  4. COSTACOU T, Guo J, Miller RG, Orchard TJ, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:985.
    PubMed     Text format    


  5. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes - Authors' reply.
    Lancet. 2019;393:985-986.
    PubMed     Text format    


  6. SNAITH JR, Holmes-Walker DJ, Girgis CM, Greenfield JR, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:984-985.
    PubMed     Text format    


  7. XIAO F, Liu M, Wang XF
    Involuntary choreiform movements in a diabetic patient.
    Lancet. 2019;393:1033.
    PubMed     Text format    


    February 2019
  8. BERGENSTAL RM, Johnson M, Passi R, Bhargava A, et al
    Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial.
    Lancet. 2019 Feb 22. pii: S0140-6736(19)30368.
    PubMed     Text format     Abstract available


    January 2019
  9. STEDMAN M, Lunt M, Livingston M, Fryer AA, et al
    The costs of drug prescriptions for diabetes in the NHS.
    Lancet. 2019;393:226-227.
    PubMed     Text format    


  10. THE LANCET
    Modernising the NHS: leading the way with diabetes.
    Lancet. 2019;393:200.
    PubMed     Text format    


  11. VERMA S, Juni P, Mazer CD
    Pump, pipes, and filter: do SGLT2 inhibitors cover it all?
    Lancet. 2019;393:3-5.
    PubMed     Text format    


    December 2018
  12. SANYAL A, Charles ED, Neuschwander-Tetri BA, Loomba R, et al
    Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Lancet. 2018 Dec 13. pii: S0140-6736(18)31785.
    PubMed     Text format     Abstract available


  13. THE LANCET
    Type 2 diabetes: the urgent need to protect young people.
    Lancet. 2018;392:2325.
    PubMed     Text format    


    November 2018
  14. UNAMUNO X, Fruhbeck G
    Lorcaserin: balancing efficacy with potential risks.
    Lancet. 2018;392:2239-2240.
    PubMed     Text format    


  15. STUMVOLL M, Tschop M
    Twice the benefits with twincretins?
    Lancet. 2018;392:2142-2144.
    PubMed     Text format    


  16. ZELNIKER TA, Wiviott SD, Raz I, Im K, et al
    SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Lancet. 2018 Nov 9. pii: S0140-6736(18)32590.
    PubMed     Text format     Abstract available


    October 2018
  17. TAYLOR R, Adamson AJ, Sattar N, Lean MEJ, et al
    VLCD for weight loss and remission of type 2 diabetes? - Authors' reply.
    Lancet. 2018;392:1307.
    PubMed     Text format    


  18. AHMAD N, Alfaris N
    VLCD for weight loss and remission of type 2 diabetes?
    Lancet. 2018;392:1306-1307.
    PubMed     Text format    


  19. BOHULA EA, Scirica BM, Inzucchi SE, McGuire DK, et al
    Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.
    Lancet. 2018 Oct 3. pii: S0140-6736(18)32328.
    PubMed     Text format     Abstract available


  20. FRIAS JP, Nauck MA, Van J, Kutner ME, et al
    Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Lancet. 2018 Oct 3. pii: S0140-6736(18)32260.
    PubMed     Text format     Abstract available


  21. GALDERISI A, Sherr JL
    Enlarging the loop: closed-loop insulin delivery for type 1 diabetes.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32329.
    PubMed     Text format    


  22. TAUSCHMANN M, Thabit H, Bally L, Allen JM, et al
    Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)31947.
    PubMed     Text format     Abstract available


  23. HERNANDEZ AF, Green JB, Janmohamed S, D'Agostino RB Sr, et al
    Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32261.
    PubMed     Text format     Abstract available


  24. MAFHAM M, Preiss D
    HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32348.
    PubMed     Text format    


    September 2018

  25. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4.
    Lancet. 2018;392:1072-1088.
    PubMed     Text format     Abstract available


    August 2018
  26. KLUGER AY, McCullough PA
    Semaglutide and GLP-1 analogues as weight-loss agents.
    Lancet. 2018;392:615-616.
    PubMed     Text format    


  27. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.
    Lancet. 2018;392:477-486.
    PubMed     Text format     Abstract available


  28. BASINA M, Maahs DM
    Age at type 1 diabetes onset: a new risk factor and call for focused treatment.
    Lancet. 2018;392:453-454.
    PubMed     Text format    


  29. MCCALL C
    Biosimilars for insulin: a cost-saving alternative?
    Lancet. 2018;392:463-464.
    PubMed     Text format    


    July 2018
  30. PALMER SC, Strippoli GFM
    Metformin as first-line treatment for type 2 diabetes.
    Lancet. 2018;392:120.
    PubMed     Text format    


    June 2018
  31. RAYNER CK, Horowitz M
    Agonism of receptors in the gut-pancreas axis in type 2 diabetes: are two better than one?
    Lancet. 2018 Jun 22. pii: S0140-6736(18)30936.
    PubMed     Text format    


  32. AMBERY P, Parker VE, Stumvoll M, Posch MG, et al
    MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
    Lancet. 2018 Jun 22. pii: S0140-6736(18)30726.
    PubMed     Text format     Abstract available


  33. LANGENBERG C, Lotta LA
    Genomic insights into the causes of type 2 diabetes.
    Lancet. 2018;391:2463-2474.
    PubMed     Text format     Abstract available


  34. DIMEGLIO LA, Evans-Molina C, Oram RA
    Type 1 diabetes.
    Lancet. 2018;391:2449-2462.
    PubMed     Text format     Abstract available


  35. PATEL T, Tesfaldet B, Chowdhury I, Kettermann A, et al
    Endpoints in diabetes cardiovascular outcome trials.
    Lancet. 2018;391:2412.
    PubMed     Text format    


  36. STEYN M, Couchman L, Coombes G, Earle KA, et al
    A herbal treatment for type 2 diabetes adulterated with undisclosed drugs.
    Lancet. 2018;391:2411.
    PubMed     Text format    


  37. THE LANCET
    Untangling the complications of diabetes.
    Lancet. 2018;391:2389.
    PubMed     Text format    


    May 2018
  38. BENNETT PH
    Diabetes mortality in the USA: winning the battle but not the war?
    Lancet. 2018 May 18. pii: S0140-6736(18)30843.
    PubMed     Text format    


  39. GREGG EW, Cheng YJ, Srinivasan M, Lin J, et al
    Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data.
    Lancet. 2018 May 18. pii: S0140-6736(18)30314.
    PubMed     Text format     Abstract available


    March 2018
  40. CHATTERJEE S, Khunti K, Davies MJ
    Type 2 diabetes - Authors' reply.
    Lancet. 2018;391:1262.
    PubMed     Text format    


  41. TATE AR
    Type 2 diabetes.
    Lancet. 2018;391:1261-1262.
    PubMed     Text format    


  42. BOUSSAGEON R, Roustit M, Gueyffier F, Tudrej BV, et al
    Type 2 diabetes.
    Lancet. 2018;391:1261.
    PubMed     Text format    


    February 2018
  43. BHATT DL
    CABG the clear choice for patients with diabetes and multivessel disease.
    Lancet. 2018 Feb 22. pii: S0140-6736(18)30424.
    PubMed     Text format    


  44. SARHAN MB, Ghandour R, Rmeileh NMEA
    The effectiveness of counselling interventions in reducing HbA1c concentrations in patients with type 2 diabetes: a modelling study.
    Lancet. 2018;391 Suppl 2:S30.
    PubMed     Text format     Abstract available


  45. SAMAN KA, Massad S, Ibaid AA, Anan H, et al
    Factors associated with depression in patients with type 2 diabetes in the Gaza Strip: a cross sectional study.
    Lancet. 2018;391 Suppl 2:S19.
    PubMed     Text format     Abstract available


  46. CANALI G, Tittle V, Seita A
    Medication adherence by Palestine refugees living in Jordan who have diabetes: a cross-sectional study.
    Lancet. 2018;391 Suppl 2:S13.
    PubMed     Text format     Abstract available


  47. BERGENSTAL RM
    Continuous glucose monitoring: transforming diabetes management step by step.
    Lancet. 2018 Feb 15. pii: S0140-6736(18)30290.
    PubMed     Text format    


  48. HEINEMANN L, Freckmann G, Ehrmann D, Faber-Heinemann G, et al
    Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.
    Lancet. 2018 Feb 15. pii: S0140-6736(18)30297.
    PubMed     Text format     Abstract available


    January 2018
  49. BARNETT R
    Type 1 diabetes.
    Lancet. 2018;391:195.
    PubMed     Text format    


    December 2017
  50. UUSITUPA M
    Remission of type 2 diabetes: mission not impossible.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33100.
    PubMed     Text format    


  51. LEAN ME, Leslie WS, Barnes AC, Brosnahan N, et al
    Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33102.
    PubMed     Text format     Abstract available


    November 2017
  52. BROWN DM, Wykoff CC
    Intravitreal aflibercept for proliferative diabetic retinopathy.
    Lancet. 2017;390:2141.
    PubMed     Text format    


  53. SIVAPRASAD S, Prevost AT, Vasconcelos J, Riddell A, et al
    Intravitreal aflibercept for proliferative diabetic retinopathy - Authors' reply.
    Lancet. 2017;390:2141-2142.
    PubMed     Text format    


  54. LIU L, Tham YC, Cheng CY
    Intravitreal aflibercept for proliferative diabetic retinopathy.
    Lancet. 2017;390:2140-2141.
    PubMed     Text format    


    October 2017
  55. MCGAVOCK J, Wicklow B, Dart AB
    Type 2 diabetes in youth is a disease of poverty.
    Lancet. 2017;390:1829.
    PubMed     Text format    


    September 2017
  56. GARG SK, Polsky S
    Continuous glucose monitoring in pregnant women with type 1 diabetes.
    Lancet. 2017 Sep 14. pii: S0140-6736(17)32449.
    PubMed     Text format    


  57. FEIG DS, Donovan LE, Corcoy R, Murphy KE, et al
    Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial.
    Lancet. 2017 Sep 14. pii: S0140-6736(17)32400.
    PubMed     Text format     Abstract available


  58. JEFFCOATE W, Barron E, Lomas J, Valabhji J, et al
    Using data to tackle the burden of amputation in diabetes.
    Lancet. 2017 Sep 11. pii: S0140-6736(17)32401.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: